Skip to content

Study · Non-randomized trial · n = 771 · 2006

4 results

Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.

Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH

Bone24 Mar 2006Cited by 54 (Europe PMC)

PMID16563890 (opens in a new tab)DOI10.1016/j.bone.2006.02.003 (opens in a new tab)PepBankPUB-16563890
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In osteoporotic postmenopausal women in the PINP subset, teriparatide reduced fracture risk versus placebo.

    In plain wordsIn women with osteoporosis in the PINP subset, teriparatide reduced fracture risk compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseFracture risk in PINP subset
    Study

    n = 771

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 mcg/dayAs given in this study (human).

    Measurements

    Fracture risk
    5.5%
    teriparatide, PINP subset
    Fracture risk
    17.7%
    placebo, PINP subset
    P value
    < 0.05 NA
    teriparatide versus placebo, PINP subset

    Source sentences

    Summary
    Teriparatide significantly reduced the risk of fracture [four BTM subset (n = 520), placebo = 14.3%, teriparatide = 5.8%, P < 0.05; PINP subset (n = 771), placebo = 17.7%, teriparatide = 5.5%, P < 0.05].
    2 context sentences
    Summary · context
    We examined data from the Fracture Prevention Trial, a study designed to determine the effect of teriparatide 20 mcg/day and teriparatide 40 mcg/day on vertebral and nonvertebral fracture risk in postmenopausal women with osteoporosis.
    Summary · context
    BTM were analyzed in two subsets of women within the Fracture Prevention Trial, and included serum bone-specific alkaline phosphatase (BSAP), serum carboxy-terminal extension peptide of procollagen type I (PICP), serum amino-terminal extension peptide of procollagen type I (PINP), urinary free deoxy…
  2. 02HumanNon-randomized trialEfficacy outcome

    In osteoporotic postmenopausal women in the four-marker subset, teriparatide reduced fracture risk versus placebo.

    In plain wordsIn women with osteoporosis in the four-marker subset, teriparatide reduced fracture risk compared with placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseFracture risk in four-marker subset
    Study

    n = 520

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 or 40 mcg/dayAs given in this study (human).

    Measurements

    Fracture risk
    5.8%
    teriparatide, four BTM subset
    Fracture risk
    14.3%
    placebo, four BTM subset
    P value
    < 0.05 NA
    teriparatide versus placebo

    Source sentences

    Summary
    Teriparatide significantly reduced the risk of fracture [four BTM subset (n = 520), placebo = 14.3%, teriparatide = 5.8%, P < 0.05; PINP subset (n = 771), placebo = 17.7%, teriparatide = 5.5%, P < 0.05].
    2 context sentences
    Summary · context
    We examined data from the Fracture Prevention Trial, a study designed to determine the effect of teriparatide 20 mcg/day and teriparatide 40 mcg/day on vertebral and nonvertebral fracture risk in postmenopausal women with osteoporosis.
    Summary · context
    BTM were analyzed in two subsets of women within the Fracture Prevention Trial, and included serum bone-specific alkaline phosphatase (BSAP), serum carboxy-terminal extension peptide of procollagen type I (PICP), serum amino-terminal extension peptide of procollagen type I (PINP), urinary free deoxy…

Studies that did not test the peptide alone2

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    In these women, teriparatide-mediated absolute fracture risk reduction was greatest with high pretreatment bone turnover.

    In plain wordsIn these women, teriparatide reduced absolute fracture risk most when pretreatment bone turnover was high.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseAbsolute fracture risk reduction by pretreatment turnover
    Study

    n: not reported in source

    Comparator
    Women with lower pretreatment bone turnover
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Teriparatide-mediated absolute risk reduction was greatest for women with high pretreatment bone turnover;
    2 context sentences
    Summary · context
    We examined data from the Fracture Prevention Trial, a study designed to determine the effect of teriparatide 20 mcg/day and teriparatide 40 mcg/day on vertebral and nonvertebral fracture risk in postmenopausal women with osteoporosis.
    Summary · context
    BTM were analyzed in two subsets of women within the Fracture Prevention Trial, and included serum bone-specific alkaline phosphatase (BSAP), serum carboxy-terminal extension peptide of procollagen type I (PICP), serum amino-terminal extension peptide of procollagen type I (PINP), urinary free deoxy…

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome

    In these women, teriparatide-mediated relative fracture risk reduction was independent of pretreatment bone turnover.

    In plain wordsIn these women, teriparatide's relative fracture risk reduction did not depend on pretreatment bone turnover.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeRelative fracture risk reduction by pretreatment turnover
    Study

    n: not reported in source

    Comparator
    Different pretreatment bone turnover levels
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    however, the relative fracture risk reduction was independent of pretreatment bone turnover.
    2 context sentences
    Summary · context
    We examined data from the Fracture Prevention Trial, a study designed to determine the effect of teriparatide 20 mcg/day and teriparatide 40 mcg/day on vertebral and nonvertebral fracture risk in postmenopausal women with osteoporosis.
    Summary · context
    BTM were analyzed in two subsets of women within the Fracture Prevention Trial, and included serum bone-specific alkaline phosphatase (BSAP), serum carboxy-terminal extension peptide of procollagen type I (PICP), serum amino-terminal extension peptide of procollagen type I (PINP), urinary free deoxy…

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.